Anthropic Pivots to Drug Discovery with New AI Workbench, Claude Science
Leading AI developer Anthropic has launched its own internal drug discovery program, targeting neglected diseases, alongside a new "AI workbench for scientists" called Claude Science.
✨ This content was summarized and interpreted by AI; it may contain errors — please verify accuracy with the original sources. Learn more
Listen to this story
Anthropic, a leading AI developer, has made a bold pivot beyond merely supplying AI tools, announcing the launch of its own internal drug discovery program at "The Briefing: AI for Science" event this week. This significant strategic shift, revealed on June 30, sees the company initially targeting "neglected diseases" often deemed commercially unattractive by traditional pharmaceutical firms. The ambition is to gain firsthand experience in drug development, fostering a "tight feedback loop" essential for refining its newly unveiled Claude Science.
Claude Science is an "AI workbench for scientists" designed to consolidate fragmented research tools and datasets into a unified environment. It streamlines scientific workflows, capable of generating publication-ready figures, 3D protein structures, and other scientific visuals, alongside auditable code. Available in beta for Pro, Max, Team, and Enterprise users on macOS and Linux, the platform integrates over 60 scientific databases and tools, facilitating literature analysis, complex data interpretation, and large-scale computing workflows in a fraction of the time. This expansion builds on Anthropic's growing healthcare footprint, including the April acquisition of AI biotech Coefficient Bio and a $200 million grant to the Gates Foundation.
This dual strategy positions Anthropic not just as an AI vendor, but as a direct participant in the scientific process, aiming to accelerate discovery and innovation by directly experiencing industry challenges. While AI promises to compress decades of scientific progress into years, as CEO Dario Amodei has suggested, successful drug development remains inherently lengthy and capital-intensive. However, by focusing on neglected diseases, Anthropic also aligns with a public benefit mission, potentially addressing critical unmet medical needs. The success of this ambitious move will be a critical test of AI's transformative power in pharmaceuticals, setting a new competitive bar for rivals like OpenAI and Google.